Effect of 13-cis-retinoic acid and α-interferon on transforming growth factor in patients with rising prostate-specific antigen

Clinical Cancer Research

Volumn 3, Issue 11, 1997, Pages 1999-2004

  DiPaola, Robert S ^a,c   Weiss, Robert E ^b,c   Cummings, Kenneth B ^b,c   Kong, Feng Ming ^d   Jirtle, Randy L ^d   Anscher, Mitchell ^d   Gallo, Jose ^c   Goodin, Susan ^c   Thompson, Sharon ^c   Rasheed, Zeeshan ^c   Aisner, Joseph ^a,c   Todd, Mary B ^a,c  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTANE; ALPHA INTERFERON; ISOTRETINOIN; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT ALPHA2A INTERFERON; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRY SKIN; FATIGUE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2A; ISOTRETINOIN; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 0030665439     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lightner, D. J., Lange, P. H., Reddy, P. K., and Moore, L. Prostate-specific antigen and local recurrence after radical prostatectomy. J Urol., 144: 921-926, 1990.
2. Hudson, M. A., Bahnson, R. R., and Catolona, W. J. Clinical use of prostate-specific antigen in patients with prostate cancer. J Urol., 142: 1011-1017, 1989.
3. Chauvet, B., Felix-Faure, C., Lupsascka, N., Fijuth, J., Brewer, Y., Davin, J., Kirscher, S., and Reboul, F. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy. J. Clin. Oncol., 12: 1402-1407, 1994.
4. Ritter, M. A., Messing, E. M., Shanahan, T. G., Potts, S., Chappell, R. J., and Kinsella, T. J. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J. Clin. Oncol., 10: 1208-1217, 1992.
5. Zagars, G. K., and von Eschenbach, A. C. Prostate-specific antigen: an important marker for prostate cancer treated by external beam radiation therapy. Cancer (Phila.), 72: 538-548, 1993.
6. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W. K., Hsieh, J., Tu, S., and Campbell, M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6944, 1992.
7. Raffo, A. J., Perlman, H., Chen, M. W., Day, M. L., Streitman, J. S., and Buttyan, R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res., 55: 4438-4445, 1995.
8. Tu, S., McConnell, K., Marin, M. C., Campbell, M. L., Fernandez, A., von Eschenbach, A. C., and McDonnell, T. J. Combination Adriamycin and suramin induces apoptosis in bcl-2-expressing prostate carcinoma cells. Cancer Lett., 93: 147-155, 1995.
9. Fong, C., Sutkowski, D. M., Braun, E. J., Bauer, K. D., Sherwood, E. R., Lee, C., and Kozlowski, J. M. Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. J. Urol., 149: 1190-1194, 1993.
10. Hwang, M. S., Thomson, K. L., and Ahn, C. H. p53-independent induction of p21 and apoptosis by all-trans-retinoic acid and 9-cis-retinoic acid in human prostate cell lines. Proc. Am. Assoc. Cancer Res., 36: 10, 1995.
11. Pienta, K., Nguyen, N. M., and Lehr, J. E. Treatment of prostate cancer in the rat with the synthetic retinoid fenetinide. Cancer Res., 53: 224-226, 1993.
12. Lippman, S. M., Kavanagh, J. J., Paredes-Espinoza, M., Delgadillo-Madrueno, F., Paredes-Casillas, P., Hong, W. K., Holdener, E., and Krakoff, I. H. 13-cis-Retinoic acid plus interferon α2a; highly active systemic therapy for squamous cell carcinoma of the cervix. J. Natl. Cancer Inst., 84: 241-245, 1992.
13. Lippman, S. M., Parkinson, D., Intri, L. M., Weber, R. S., Schantz, S. P., Ota, D. M., Schusterman, M. A., Krakoff, I. H., Gutterman, J. U., and Hong, W. K. 13-cis-Retinoic acid and interferon α2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J. Natl. Cancer Inst., 84: 235-240, 1992.
14. Sridhara, R., Eisenberger, M. A., Sinibald, V. J., Reynol, M., and Egorin, M. J. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J. Clin. Oncol., 13: 2944-2953, 1995.
15. Kelly, W. K., Curley, T., Liebertz, C., Kim, B., and Scher, H. Phase II trial of 13-cis-retinoic acid and interferon α2a in patients with adenocarcinoma of the prostate. Proc. Am. Soc. Clin. Oncol., 15: 254, 1996.
16. Goldstein, D., O'Leary, M., Mitchen, J., Borden, E. C., and Wilding, G. Effects of interferon β SER and transforming growth factor β on prostatic cell lines. J. Urol., 146: 1173-1177, 1991.
17. Roberts, A. B., Lamb, L. C., Newton, D. L., Sporn, M. B., DeLarco, J. E., and Todaro, G. J. Transforming growth factors: isolation of polypeptides from visually and chemically transformed cells by acid/ ethanol extraction. Proc. Natl. Acad. Sci. USA, 77: 3494-3498, 1980.
18. Kong, F., Anscher, M. S., Murase, T., Abbott, B. D., Iglehart, J. D., and Jirtle, R. L. Elevated plasma transforming growth factor β1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann. Surg., 222: 155-162, 1995.
19. Higano, C. S., and Chielens, D. α-Interferon and cis-retinoic acid in combination for treatment of hormone-refractory prostate cancer: preliminary results of an ongoing trial. Proc. Am. Soc. Clin. Oncol., 15: 243, 1996.
20. lavonovic, V., Melman, A., Davis-Joseph, B., Valcic, M., and Geliebter, J. Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nat. Med., 1: 282-283, 1995.
21. Kopp, A., Jonat, W., Schmahl, M., and Knabbe, C. Transforming growth factor β2 (TGF-β2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res., 55: 4512-4515, 1995.
22. Butta, A., Maclennan, K., Flanders, K. C., Sacks, N., Smith, I., McKinna, A., Dowsett, M., Wakefield, L. M., Sporn, M. B., Baum, M., and Colletta, A. Induction of transforming growth factor β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res., 52: 4262-4264, 1992.
23. Batocchi, A. P., Evoli, A., Servidei, S., Palmisani, M. T., Apollo, F., and Tonali, P. Myasthenia gravis during interferon α therapy. Neurology, 45: 382-383, 1995.